Oxidative Stress, Neuroinflammation, and Neuronal Loss Start in Midlife: a 7 Tesla Magnetic Resonance Spectroscopy Healthy Adult Age-Span Study

Flavie E. Detcheverry[1,2,3], Sneha Senthil[4,5], Rozie Arnaoutelis[4,5], Samson Antel[4,5], Haz-Edine Assemlal[5,6], Zahra Karimaghaloo[6], Douglas L. Arnold[4,5], Jamie Near[7], Sridar Narayanan[4,5], AmanPreet Badhwar[1,2,3]

[1]Multiomics Investigation of Neurodegenerative Diseases (MIND) lab, Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal (CRIUGM), Montreal, QC, Canada;

[2]Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, QC, Canada;

[3]Institute of Biomedical Engineering, University of Montreal, Montreal, QC, Canada;

[4]Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada;

[5]McConnell Brain Imaging Centre, Montreal Neurological Institute-Hospital, Montreal, QC, Canada;

[6]NeuroRx Research, a Clario Company, Montreal, QC, Canada;

[7]Sunnybrook Research Institute, Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.

Correspondence

AmanPreet Badhwar, MSc, PhD

Multiomics Investigation of Neurodegenerative Diseases (MIND) lab, Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal (CRIUGM)

4565 Chemin Queen Mary, Montréal, Quebec, H3W 1W5, Canada

Email: amanpreet.badhwar@umontreal.ca

Telephone: 001 (514) 340-3540, extension 3345

ABSTRACT

INTRODUCTION: While changes associated with age-related diseases, like oxidative stress, begin in midlife, most aging studies focused on older individuals. Our study assessed *in vivo* brain metabolites in healthy adults, including the understudied middle-age group.

METHODS: 7T magnetic resonance spectroscopy data were acquired from 87 healthy adults (45 women) aged 20-79 years. Levels of eight metabolites were measured in posterior cingulate cortex (PCC) and centrum semiovale white matter (CSWM).

RESULTS: With increasing age, we found (a) lower glutathione and glutamate, and higher *myo*-inositol in PCC, and (b) lower *N*-acetylaspartate and glutamate, and higher *N*-acetylaspartyl glutamate, *myo*-inositol, and total creatine in CSWM. Notably, these changes started in midlife and were largely driven by age-related changes in women.

DISCUSSION: Overall, we found evidence that (a) oxidative stress, (b) neuroinflammation, and (c) neuronal loss begin in midlife of healthy adults. Targeting these mechanisms in midlife may slow brain aging and reduce the risks of developing age-related diseases.

1. INTRODUCTION

Higher life expectancy is accompanied by higher rates of chronic diseases, including age-related neurodegenerative diseases (NDDs) [1]. Thus, understanding biological processes and mechanisms in healthy aging is key to uncovering changes that might contribute to age-related diseases. Evidence suggests that NDD-associated structural, functional, and molecular changes begin in midlife (i.e., 40+ years) [2–4], and might be accelerated by menopause in women [2]. Therefore, the transition from middle- to older-age is crucial for future health and might offer a window for prevention of cognitive decline. In particular, the 2024 *Lancet's* Commission on Dementia reported that 45% of dementia cases could be prevented if all 14 identified risk factors were adequately addressed, with ten occurring in midlife and potentially reducing dementia risk by 30% [5]. Despite this, the majority of aging and age-related disease studies have focused mostly on the older population (60+ years).

Oxidative stress has been hypothesized to be a contributor to age-related decline [6,7]. Oxidative stress results from an imbalance between the production and neutralization of reactive oxygen species (ROS), such as hydrogen peroxide [8]. This imbalance is amplified in midlife with ROS accumulation and lower energy production, building over time into a less efficient antioxidant system and overall homeostasis loss [9]. Notably, in middle-aged women, menopause has been associated with higher oxidative stress [10]. The brain is the most energetically demanding organ [11–14], and hub regions like the posterior cingulate cortex (PCC) are more vulnerable to oxidative stress [15,16]. Antioxidants, with the most prevalent being glutathione (GSH), can help neutralize ROS and protect against oxidative damage [17–19]. GSH and other metabolites can be assessed in the brain *in vivo* using magnetic resonance spectroscopy (MRS). Using MRS, GSH levels were found to (a) decrease

with age in precuneus, cingulate, and occipital regions, reflecting lower antioxidant capacity, and (b) increase in frontal and sensorimotor regions, suggesting a compensatory mechanism in response to increased oxidative stress in older adults [8].

MRS-detected metabolites most studied include *N*-acetylaspartate (NAA; neuroaxonal marker [14]); *N*-acetylaspartyl glutamate (NAAG; neuromodulator [20]), often reported with NAA as total NAA (tNAA); glutamate (Glu; main excitatory neurotransmitter [21]); choline (Cho; membrane turnover marker [22]); *myo*-inositol (mI; astroglial marker [23]); and creatine (Cr; neuronal energy substrate [24]). Although decreased NAA and Glu, and increased Cho, mI, and Cr levels were commonly reported with increasing age, there lacks consensus [12,14,25], with variable ages and number of included participants across studies being a likely contributor. Specifically, studies investigating middle-aged healthy adults (40-59 years) are lacking, an age group where changes that increase the risk of developing an NDD later in life are thought to appear [26,27].

The variety of MRS parameters and quantification techniques (e.g., ratios to Cr or another metabolite) can influence metabolite detection and complicate results interpretation. For example, using 1.5 tesla (T), McIntyre et al. reported higher tNAA and total Cr (tCr = Cr + phosphocreatine) levels in centrum semiovale white matter (CSWM) using short echo time (TE = 30 ms), and no significant findings using long TE (136 ms) [28]. There is also a scarcity of studies using 7T MRS, a magnet strength providing better signal-to-noise ratio, improved spectral resolution [29–32], and excellent reproducibility of low-concentration metabolites measurements (e.g., GSH) [8]. Finally, most age-related metabolite findings are region-specific [8,33–35], which might be due to the underlying tissue composition, as some metabolites are preferentially located in certain cell types (e.g., GSH in glia).

Our study aims to assess brain metabolite level variations in healthy adults, including the often understudied middle-aged adults, using 7T MRS in PCC and CSWM, two areas showing altered microstructure, metabolism, and connectivity in aging and NDDs [15,16,36–38]. Given the increased sensitivity and specificity provided by ultra-high field strength, ultra-short TE, and long repetition time (TR) [39], we were able to reliably measure levels of eight metabolites. Specifically, we assessed the associations between metabolite levels and (a) age, (b) sex, and (c) functional test scores.

2. METHODS

2.1 Participants

87 healthy adults (45 women) were divided into three age groups (Younger, 20-39 years, N = 32; Middle-aged, 40-59 years, N = 27; Older, 60-79 years, N = 28) were included. Participants were recruited from the Montreal community using the word-of-mouth method, as well as from the Banque de Participants from the Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal (CRIUGM). All participants were cognitively unimpaired and overall healthy. Exclusion criteria included cognitive complaint/worry, stroke, head trauma, psychiatric disorders, and magnetic resonance imaging (MRI)-related contraindications, such as metal in the body (e.g., pacemaker), claustrophobia, and pregnancy. Ethical approval was obtained from the aging-neuroimaging research ethics committee of the CIUSSS du Centre-Sud-de-île-de-Montréal (CIUSSS-CSMTL), and from the McGill University Institutional Review Board, Faculty of Medicine and Health Sciences. Written informed consent was obtained from all participants.

2.2 Functional Testing

Three measures sensitive to processing speed, manual dexterity, and gait/mobility were acquired: (a) Processing Speed Test (PST) [40], based on the Symbol-Digit Modalities Test (SDMT), measuring processing speed, (b) the 9-hole Peg Test (9HPT), assessing manual dexterity, and (c) the Timed 25-foot Walk Test (T25FW) for gait and mobility. A description of each test has been provided in Supplementary Table S1.

2.3 MR Acquisition

In vivo brain data were acquired on a 7T Siemens Terra MR scanner at the McConnell Brain

Imaging Centre of the Montreal Neurological Institute-Hospital (MNI; McGill University), using an 8-channel transmit and 32-channel receive head coil. T_1-weighted Magnetization-Prepared 2 Rapid Acquisition Gradient-Echo (MP2RAGE) images [41] were obtained for localization (TR/TE = 5000/2.33 ms; field of view (FOV): 240 mm; slice thickness = 0.70 mm; 1 average; 240 slices; acceleration factor = 3; acquisition time: 8 min 55 s). Using these anatomical images as reference, two MRS single-voxels were positioned (Fig. 1), one over the PCC/precuneus, a metabolically active hub region [15] (predominantly grey matter, GM), and the other over the CSWM, a region prone to age-related white matter damage [42] (predominantly white matter, WM). The PCC voxel (30 x 20 x 20 mm³) was positioned at midline aligned posterior to the corpus callosum, and the CSWM voxel (30 x 15 x 15 mm³) was placed in the left supraventricular WM. MRS spectra were acquired using the STimulated Echo Acquisition Mode (STEAM) sequence with the following parameters: TR/TE = 5000/8 ms; mixing time (TM) = 40 ms; flip angle = 90°; 64 to 96 averages in PCC, and 96 to 128 averages in CSWM; 4096 points; 5000 Hz spectral bandwidth; and acquisition time: 5 to 8 min in PCC, and 8 to 10 min in CSWM. Shimming was performed automatically using the Siemens "brain" B0 shim mode [43], and VAriable Power and Optimized Relaxations delays (VAPOR) method was used for water suppression [44,45]. Non-suppressed water spectra were acquired for eddy current correction and water reference quantification (TR/TE = 5000/8.00 ms; TM = 40 ms; 8 averages). Each scan lasted about 1 hour 15 minutes.

Figure 1. Single-voxel placement per age group (i.e., Younger, Middle-aged, Older) in posterior cingulate cortex/precuneus; and left centrum semiovale white matter. *Abbreviations:* Gln, glutamine; Glu, glutamate; mI, *myo*-inositol; NAA, *N*-acetylaspartate; NAAG, *N*-acetylaspartyl glutamate; PCr, phosphocreatine; RL x AP x FH, right-left x anterior-posterior x foot-head; tCho, total choline; tCr, total creatine. Glutathione (GSH) was not labeled on the example spectrum due to its complex structure with multiple overlapping resonances.

2.4 Image Processing and Analysis

T_1-weighted images were segmented into GM, WM, and cerebrospinal fluid (CSF) using the locally-developed Brain Tissue Composition-Net (BTCNet) pipeline, based on a published framework [46]. Each MRS voxel was converted into a binary mask image in the T_1-weighted image space using locally-developed software, built using the MINC Toolkit (https://bic-mni.github.io), and the fractions of the MRS voxel composed of GM, WM, and CSF were calculated.

2.5 Spectral Processing and Quantification

2.5.1 MRS Preprocessing and Processing

Raw MRS data was preprocessed using the FID Appliance (FID-A) [47] in Matlab (v2022b; MathWorks Inc. Natick, USA), before spectral fitting. Eddy current correction and spectral analysis were performed in LCModel (v6.3; Provencher Inc., Canada) [48], using a basis set consisting of 21 metabolite basis spectra and 9 macromolecule basis spectra. Specifically, the following metabolites were included in the basis set: alanine (Ala), aspartate (Asp), phosphocholine (PCh), creatine (Cr), phosphocreatine (PCr), gamma-aminobutyric acid (GABA), glutamine (Gln), glutamate (Glu), glutathione (GSH), glycine (Gly), *myo*-inositol (Ins), lactate (Lac), *N*-acetylaspartate (NAA), scyllo-inositol (Scyllo), taurine (Tau), glucose (Glc), *N*-acetylaspartyl glutamate (NAAG), glycerophosphocholine (GPC), phosphatidylethanolamine (PE), serine (Ser), ascorbate (Asc), and nine macromolecule resonances (MM1-MM9). Macromolecular frequencies were: 0.89, 1.2, 1.39, 1.63, 1.98, 2.28, 2.98, 3.19, and 3.75 ppm.

2.5.2 Absolute Quantification

Following expert consensus recommendations [49], quantification of metabolite signal intensity to absolute concentrations was performed using the equation (Eq. 1; Supplementary Material S1) provided by Dhamala et al. [50]. T_1 and T_2 relaxation time constants of water were obtained from the literature [51,52]: T_1 (WM) = 1120 ms; T_2 (WM) = 55 ms; T_1 (GM) = 2130 ms; T_2 (GM) = 50 ms; T_1 (CSF) = 4425 ms; T_2 (CSF) = 141 ms. Assumed visible water concentration was 36100 mmol/L in WM, 43300 mmol/L in GM, and 53800 mmol/L in CSF [50]. Voxel-specific tissue water concentrations were calculated per participant using Eq. 2 (Supplementary Material S1). Given that our TR >> TE, T_2 (but not T_1) relaxation times of

metabolites were included from the literature [53] (see Supplementary Table S2). Finally, GM, WM, and CSF volume fractions within the two MRS voxels were determined from structural data, and ranges are provided in Supplementary Table S3.

2.5.3 Quality Control

Data quality control was performed via visual inspection of the spectrum, fit, baseline, and residual, as per recommendation [54]. Signal-to-Noise Ratio (SNR) and full-width at half maximum (FWHM) were also inspected for each spectrum. Metabolites where the Cramér-Rao Lower Bound (CRLB) estimates (as provided by LCModel), averaged across all participants, exceeded 20% were considered unreliable and systematically excluded, following a commonly used threshold [17,55–57]. The resulting mean CRLBs for included metabolites per region of interest are shown in Supplementary Table S4.

2.6 Statistical Analysis

All statistical analyses were conducted in R (v4.4.1; R Core Team) within RStudio (v2024.09.0; RStudio, PBC, USA). General linear models (GLMs) were used to assess the relationship between metabolite levels and (a) age and (b) age groups, controlling for sex. To assess the effect of sex on age-related metabolite changes, participants were divided into two groups (i.e., men and women), and the associations with age and age group were performed independently within each sex. To investigate whether menopausal status had an impact on age-related metabolite level variations, women were further categorized based on self-reported pre- and post-menopausal status. Additionally, to control for the effect of age in menopausal associations, the same analysis was performed in age-matched men only, based on the age cut-off of pre- vs. post-menopausal women. Finally, GLMs, controlling for age, were performed to assess the effect of metabolite levels on functional test scores, in all participants,

and in men and women separately. All statistical analyses were corrected for multiple comparisons using the false discovery rate (FDR) method at 5%. Statistical significance threshold was set at $p < 0.05$. Metabolite levels are reported in absolute concentrations expressed as institutional units.

3. RESULTS

Participant demographics are provided in Table 1. Age groups were divided as follows: young adults: 20-39 years of age; middle-aged adults: 40-59 years of age; and old adults: 60-79 years of age. After performing quality control, three participants were excluded for analyses for PCC (one man and two women in the older group) and one for CSWM (man in the younger group), resulting in 84 participants for PCC and 86 for CSWM. For all participants, there was 100% concordance between sex (biological) and gender (social), therefore the term "sex" is being used to describe both biological and social constructs.

Table 1. Participant demographics. *Abbreviations:* BMI, body-mass index = weight (kg) / [height (m)]²; SD, standard deviation.

	Younger 20-39 years	**Middle-aged** 40-59 years	**Older** 60-79 years
N (women)	32 (16)	27 (14)	28 (15)
Age (mean ± SD)	29.25 ± 5.34	51.26 ± 5.69	69.21 ± 5.83
BMI (mean ± SD)	25.89 ± 6.43	27.37 ± 5.11	27.70 ± 10.58
Education (years)	18.05 ± 2.04	16.00 ± 2.73	16.11 ± 2.39
Symbol digit modalities test	65.31 ± 8.77	56.30 ± 8.39	42.75 ± 7.13
9-hole peg test	18.81 ± 2.09	20.02 ± 2.64	21.35 ± 2.18
Timed 25-foot walk test	3.82 ± 0.57	3.90 ± 0.54	4.21 ± 0.68

3.1 Age-Specific Metabolite Level Changes

3.1.1 Age as a Continuum

After controlling for sex, increasing age (20-79 yrs) was associated with lower levels of GSH (p = 0.002) and Glu (p = 0.003), and higher levels of mI (p = 0.008) in PCC (Fig. 2). In CSWM, increasing age was associated with lower NAA (p = 0.004) and Glu (p = 0.004) levels, and higher levels of NAAG (p = 0.002), mI (p = 0.004), and tCr (p = 0.004).

Figure 2. Age-specific metabolite level changes with age as a continuum. *Abbreviations: **, p < 0.01; Gln, glutamine; Glu, glutamate; GSH, glutathione; mI, myo-inositol; NAA,*

N-acetylaspartate; NAAG, *N*-acetylaspartyl glutamate; tCho, total choline; tCr, total creatine.

3.1.2 Age Groups

When investigating metabolite level changes by age group (i.e., Middle-aged vs. Younger, Older vs. Younger, and Older vs. Middle-aged), we found similar results (Fig. 3). Specifically, in PCC, we found lower GSH and Glu levels in middle-aged (GSH: $p = 0.021$; Glu: $p = 0.041$) and older (GSH: $p = 0.003$; Glu: $p = 0.003$) adults compared to younger adults. In CSWM, relative younger adults, (a) middle-aged adults had lower levels of NAA ($p = 0.012$) and Glu (p 0.009), and higher levels of mI ($p = 0.021$), and (b) older adults had lower NAA ($p = 0.004$) and Glu ($p = 0.009$) levels, and higher NAAG ($p = 0.005$), mI ($p = 0.026$), and tCr ($p = 0.011$) levels.

Figure 3. Age-specific metabolite level changes with age groups. *Abbreviations: *, p < 0.05;* **, *p* < 0.01; Gln, glutamine; Glu, glutamate; GSH, glutathione; mI, *myo*-inositol; NAA, *N*-acetylaspartate; NAAG, *N*-acetylaspartyl glutamate; n.s., not significant; tCho, total choline; tCr, total creatine.

3.2 Sex-Specific Metabolite Level Changes

When investigating men and women as two independent groups, we found more significant associations in women, particularly in CSWM.

3.2.1 Age As A Continuum

With increasing age, men had no metabolite level changes (Fig. 4). Women had (a) lower GSH (*p* = 0.016) and Glu (*p* = 0.021) in PCC, (b) lower NAA (*p* = 0.042) and Glu (*p* = 0.031) in CSWM, and (c) higher NAAG (*p* = 0.018), mI (*p* = 0.016), tCho (*p* = 0.018), and tCr (*p* = 0.016) levels in CSWM with increasing age.

Figure 4. Sex-specific metabolite level changes with increasing age. Brown represents women

and blue represents men. *Abbreviations: *, p < 0.05; **, p < 0.01*; Gln, glutamine; Glu, glutamate; GSH, glutathione; mI, *myo*-inositol; NAA, *N*-acetylaspartate; NAAG, *N*-acetylaspartyl glutamate; tCho, total choline; tCr, total creatine.

3.2.2 Age Groups

When investigating metabolite level changes by age group within each sex, no significant findings were observed in men. In PCC, older women had significantly lower levels of GSH (p = 0.031) and Glu (p = 0.028) than younger women. In CSWM, (a) middle-aged women had higher mI (p = 0.025) levels relative to younger women, and (b) older women had lower NAA (p = 0.045) and Glu (p = 0.045) levels, and higher NAAG (p = 0.045), mI (p = 0.037), and tCr (p = 0.037) levels compared to younger women.

3.2.3 Menopausal Status

To investigate whether metabolite level changes differed by menopausal status, women were stratified based on their self-reported status. We then compared pre- and post-menopausal women (± 5 years to control for those undergoing a peri-menopausal transition phase). While we found lower GSH ($p_{unadjusted}$ = 0.022) and Glu ($p_{unadjusted}$ = 0.021) levels in PCC in post-relative to pre-menopausal women, these results did not survive multiple comparisons correction. In CSWM, post-menopausal women had significantly higher levels of mI (p = 0.034), tCho (p = 0.026), and tCr (p = 0.026), in comparison to pre-menopausal women. Additionally, in CSWM, we found lower levels of Glu ($p_{unadjusted}$ = 0.025) and higher NAAG ($p_{unadjusted}$ = 0.032) levels in post- relative to pre-menopausal women, but these results did not survive multiple comparisons correction.

In men older than 55 years relative to those younger than 45 years, we found that older men

had (a) lower GSH ($p_{unadjusted}$ = 0.030) and Glu ($p_{unadjusted}$ = 0.015) levels and higher mI ($p_{unadjusted}$ = 0.017) levels in PCC, and (b) lower NAA ($p_{unadjusted}$ = 0.030) and higher NAAG ($p_{unadjusted}$ = 0.028) levels in CSWM, but none of these results survived multiple comparisons correction.

3.3 Metabolite Levels And Functional Test Scores

No association between metabolite levels and functional test scores remained significant after correcting for multiple comparisons correction. Without correction, we found (a) T25FW score was negatively associated with Gln ($p_{unadjusted}$ = 0.023) levels in PCC and with tCho ($p_{unadjusted}$ = 0.027) levels in CSWM, and (b) 9HPT scores were positively associated with tCho ($p_{unadjusted}$ = 0.044) levels in PCC. In women, higher T25FW score (i.e., longer time to walk 25 feet) was associated with lower levels of mI ($p_{unadjusted}$ = 0.012) in CSWM, and a higher 9HPT score (i.e., worse manual dexterity) was associated with lower NAAG ($p_{unadjusted}$ = 0.021) and mI ($p_{unadjusted}$ = 0.048) levels in CSWM. Finally, in men, higher T25FW score was associated with lower levels of Gln ($p_{unadjusted}$ = 0.037) in CSWM.

With increasing age, there was a negative association with the SDMT score ($p < 0.001$), and positive associations with the T25FW ($p = 0.46$) and 9HPT ($p < 0.001$) scores. Specifically, middle-aged ($p < 0.001$) and older adults ($p < 0.001$) had lower SDMT scores (i.e., worse processing speed) than younger adults, and older adults ($p < 0.001$) also had lower scores compared to middle-aged adults. In addition, (a) older adults had a higher T25FW score than younger adults ($p = 0.015$), (b) older adults had a higher 9HPT score relative to both middle-aged ($p < 0.001$) and younger ($p < 0.001$) adults, and (c) middle-aged adults had a higher 9HPT score compared to younger adults ($p = 0.047$).

In women with increasing age, there was a negative association with the SMDT score ($p < 0.001$) and positive associations between both the T25FW ($p = 0.001$) and 9HPT ($p = 0.001$) scores. Finally, in men, age was negatively associated with the SDMT score ($p < 0.001$), and positively associated with the 9HPT score ($p = 0.001$).

4. DISCUSSION

Our study addresses a critical gap in lifespan research by including a large cohort of middle-aged adults, a pivotal period for aging and age-related disease [2–4]. We employed state-of-the-art ultra-high field MRS with expert consensus methods [49,54] to precisely quantify GSH, NAA, NAAG, Glu, Gln, mI, tCho, and tCr, providing more accurate insights into metabolic alterations in healthy aging.

Overall, our findings suggest a role of oxidative stress, neuroinflammation, and neuronal loss in healthy aging that becomes apparent in middle-age, as shown by age-related changes in levels of (a) GSH, (b) mI, tCr, and tCho, and (c) Glu, NAA, and NAAG, respectively. These three processes are highly interconnected and serve as key drivers of aging, playing a crucial role in the onset and progression of age-related neurodegenerative diseases [58–61].

4.1 Age-Related Metabolite Changes In Healthy Aging

4.1.1 Increased Oxidative Stress In Healthy Aging

MRS literature assessing GSH levels in healthy adults is limited, which might be due, in part, to the complexity of measuring GSH at lower field strength ($\leq$ 3T), given its low concentration and complex multiplet structure due to J-coupling [8]. In particular, very few studies have investigated GSH level changes in healthy adults using 7T MRS [34,62], and only one included middle-aged adults [62]. In the present study, we found lower levels of the antioxidant GSH in PCC with increasing age starting in middle-age, suggesting that oxidative damage and vulnerability to oxidative stress in GM may begin to increase around 40-50 years of age. Lower antioxidant capacity in PCC might be due to the higher energy demand of GM compared to WM, as evidenced by more than twice the oxygen consumption in GM [63]. To

meet this high energy demand, GM exhibits a higher number of mitochondria [64] that generate adenosine triphosphate (ATP) via oxidative phosphorylation (OXPHOS), the primary source of ROS [65]. Consequently, the elevated mitochondrial activity in GM, together with decreased GSH levels can ultimately lead to higher levels of oxidative stress with increasing age. Research shows altered connectivity in the Alzheimer's disease continuum, including in PCC, highlighting the vulnerability of hub regions (having high energy demands) to oxidative stress [36]. While some increase in oxidative stress is part of healthy aging, excess levels starting in middle-age may indicate early signs of pathological changes. Therefore, measuring GSH using ultra-high field MRS in hub regions like PCC could allow early detection of abnormal changes and offer a potential window for interventions to prevent further damage and reduce the risks of age-related diseases like Alzheimer's disease. To do so, studies in healthy adults across the lifespan are needed to establish normal baseline data.

4.1.2 Increased Neuroinflammation In Healthy Aging

We found higher levels of the astroglial marker mI in both PCC and CSWM, with middle-aged adults already exhibiting higher levels than younger adults in CSWM, suggesting earlier increase of gliosis and inflammation in WM than GM. Using MRS, our study is one of the first reports of increased neuroinflammation in WM starting in middle-aged healthy adults *in vivo*, with only one 7T MRS study including middle-aged adults reporting higher mI levels in GM regions [66]. In human and mouse postmortem brain tissues, increased microglial protein levels in WM were found to start in middle-age, reflective of inflammatory activity [67]. In Alzheimer's disease continuum, WM neuroinflammation has been shown to appear years before symptoms [68], and might precede GM neuroinflammation [67]. Therefore, our results show that it is possible to detect

increased neuroinflammation *in vivo* in WM prior to the one in GM, in middle-aged healthy adults.

In addition to mI, we found higher tCr levels in CSWM with increasing age. Using MRS, tCr levels have previously been thought to remain relatively high and stable throughout the brain, and used as an internal reference [69]. However, several studies reported higher tCr levels with increasing age [12,14,70], and very few reported decreases [12,14]. With increasing age, tCr levels tend to increase in muscles, where it is primarily produced [71], due to low (a) physical activity, (b) strength, and (c) meat consumption [72]. Furthermore, a smaller amount is synthesized by neurons and oligodendrocytes [71], and increased brain tCr levels may reflect a compensatory mechanism of altered energy demand [73], and of impaired brain morphology and function with age [71]. Several studies have tried modifying creatine levels using supplementation, but while results have shown increases in muscles, results in the brain have been less conclusive [71,74].

Finally, while most Glu comes from the Glu-Gln cycle between neurons and astrocytes, some Glu is synthesized from glucose in the tricarboxylic acid (TCA) cycle in astrocytes [75]. Both the Glu-Gln and the TCA cycles can be altered by oxidative stress, causing neurodegeneration and neuroinflammation [76]. Therefore, age-related decreases in Glu levels in PCC and CSWM can be reflective of neuroinflammation.

4.1.3 Increased Neuronal Loss In Healthy Aging

In CSWM, we found lower levels of the neuroaxonal marker NAA with increasing age, suggesting neuroaxonal loss starting in middle-age. This aligns with a study combining MRS with diffusion tensor imaging, showing altered WM macrostructure in middle-aged-to-older

adults partly due to axonal loss, as reflected by lower NAA levels [77]. In the literature, NAA and NAAG have often been grouped together, and reported as total NAA (tNAA). Using 7T MRS, only one study included middle-aged healthy adults and reported higher tNAA levels in older relative to middle-aged adults in hippocampus, with no significant differences compared to younger adults or in other brain regions (anterior cingulate cortex, dorsolateral prefrontal cortex, and thalamus) [66]. In addition, we found higher levels of the neuromodulator NAAG in CSWM with increasing age, highlighting the importance of separating NAAG from NAA. In contrast to NAA (or tNAA) which has been studied by most MRS studies [12,14], the literature on NAAG is sparse. For instance, NAAG levels were found to decrease in PCC and occipital cortex at 7T in older relative to younger adults (N = 33) [34], and to increase in PCC and remain stable in centrum semiovale at 3T in younger-to-older adults (N = 102) [70]. Therefore, additional studies at higher field strength are needed to reliably assess NAAG in healthy adults, including middle-age.

In PCC and CSWM, we observed age-related decreases of Glu levels, starting in middle-aged adults. Our study is one of the first investigating group differences with middle-aged adults. In particular, Glu has been reported to decrease in older adults compared to younger adults using 7T MRS in occipital cortex [34] and dorsolateral prefrontal cortex [66], and in younger adults in medial frontal cortex [78]. In PCC, lower Glu levels with age are indicative of altered glutamatergic neurotransmission and neuronal metabolism. These changes might be driven by (a) age-related alterations in proteins and transporters involved in the Glu-Gln cycle between neurons and astrocytes, as reported in humans and rodents [79,80], and (b) reduced Glu uptake due to lower density of glutamatergic receptors [75]. In particular, rodent studies have shown age-related decline of glutamatergic receptors α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and *N*-methyl *D*-aspartate

(NMDA) [75]. Therefore, this may reflect age-related changes in astrocytic function and neuronal metabolism in GM, starting in middle-age. In contrast, lower Glu levels in CSWM may be indicative of structural brain changes, including (a) loss of neuroaxonal integrity, as suggested by lower NAA levels, and (b) higher neuroinflammation, reflected by higher mI and tCr in CSWM.

4.2 Sex-Related Metabolite Changes In Healthy Aging

In women but not in men, we found that healthy aging was associated with lower PCC levels of (a) GSH, reflecting lower antioxidant capacity with increasing age in women, and (b) Glu levels, a result in line with a stronger age-related decrease of Glu levels reported in anterior cingulate cortex of healthy younger-to-middle-aged women relative to men, using 3T MRS [81]. In CSWM, we found that increasing age in women was associated with (a) higher mI, tCr, and tCho levels, reflecting higher age-related neuroinflammation in women, and (b) lower Glu and NAA levels, suggesting stronger age-related WM volume loss in women with age, as shown in post-menopausal women relative to pre-menopausal women and age-matched men [82].

A proposed reason for these reported sex-related differences in metabolite level changes in healthy aging is circulating estrogen. In particular, estradiol and other eostrogenic compounds (a) possess antioxidant properties, by protecting mitochondrial integrity and decreasing mitochondrial production of hydrogen peroxide, a major ROS [83], (b) have an anti-inflammatory role, as evidenced by lower proinflammatory markers found in serum of post-menopausal women taking hormonal therapy (i.e., oral estradiol therapy) relative to a placebo [84], (c) are protective against glutamate-induced excitotoxicity [85], and (d) have been found to increase the number of NMDA receptor binding sites [86]. However, this

estrogen-related advantage of women is lost after menopause, which typically occurs between 45 and 55 years of age [87,88]. Therefore, lower estrogen levels after menopause might (a) explain the steeper decline of GSH levels observed with increasing age in women relative to men, (b) increase immune reactivity and alter communication between the brain and the immune system, contributing to neuroinflammation [89,90], and (c) associate with lower Glu levels and increased risk of menopause-associated depression [86].

4.3 Limitations

Our study has some limitations. First, while we used advanced scanning techniques and rigorous analysis methods, we measured metabolite levels in only two single-voxels (PCC and CSWM). We employed single-voxel MRS to obtain sufficient SNR and spectral resolution to reliably quantify low-concentration metabolites such as GSH. Given the long duration of MRS acquisition and the constraint of participants' ability and willingness to remain still in the scanner, this practically limited us to two voxels within our combined MRI/MRS protocol. Future studies using spectroscopic imaging would be informative regarding the spatial distributions of metabolite changes with age, since these can be region specific, although such studies would be limited to assessing higher-concentration metabolites. Secondly, while we quantified metabolite signal intensity as absolute concentrations, values for water T_1 and T_2 relaxation times and for metabolite T_2 relaxation times were acquired from the literature rather than measured in our participants due to time constraints. In particular, T_2 relaxation times of NAA, tCr, and tCho have been reported to decrease with increasing age [91]. However, only a handful of papers reported relaxation times acquired at 7T [51–53], and none disclosed values for all three age groups (especially for middle-aged adults) and/or for all our metabolites of interest (in particular, GSH). Given this, we chose to include one relaxation time for all participants and per metabolite, in order

to reduce possible bias. Finally, we did not have biological tests done to assess menopausal status or hormonal levels, only self-reported menopausal status. Additional sex-specific and menopause-focused studies are therefore warranted, with the transition period into menopause being more carefully delineated (e.g., using the STRAW (Stages of Reproductive Aging Workshop) guidelines [92]).

5. CONCLUSION

In conclusion, our study identified age-related changes in metabolite levels as assessed using ultra-high field 7T MRS. In particular, we reported that oxidative stress, neuroinflammation, and neuronal loss start as early as middle-age in healthy adults, which could suggest a pivotal age for future health. In addition, our study provides evidence of sex-specific metabolic aging, with a potential sex hormone-related advantage of women (e.g., estrogen) lost after menopause, therefore contributing to increased oxidative stress, neuroinflammation, and neuronal loss. Future studies should focus more on middle-aged healthy adults and the transition from pre- to post-menopause in middle-aged women.

6. REFERENCES

[1] Sun X, Li X. Editorial: Aging and chronic disease: public health challenge and education reform. Front Public Health 2023;11:1175898. https://doi.org/10.3389/fpubh.2023.1175898.

[2] Dohm-Hansen S, English JA, Lavelle A, Fitzsimons CP, Lucassen PJ, Nolan YM. The "middle-aging" brain. Trends Neurosci 2024;47:259–72. https://doi.org/10.1016/j.tins.2024.02.001.

[3] Ritchie K, Ritchie CW, Yaffe K, Skoog I, Scarmeas N. Is late-onset Alzheimer's disease really a disease of midlife? Alzheimers Dement (N Y) 2015;1:122–30. https://doi.org/10.1016/j.trci.2015.06.004.

[4] Lehallier B, Gate D, Schaum N, Nanasi T, Lee SE, Yousef H, et al. Undulating changes in human plasma proteome profiles across the lifespan. Nat Med 2019;25:1843–50. https://doi.org/10.1038/s41591-019-0673-2.

[5] Livingston G, Huntley J, Liu KY, Costafreda SG, Selbæk G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 2024;404:572–628. https://doi.org/10.1016/S0140-6736(24)01296-0.

[6] Gilbert SF. Aging: The Biology of Senescence. Sinauer Associates; 2000.

[7] Iakovou E, Kourti M. A Comprehensive Overview of the Complex Role of Oxidative Stress in Aging, The Contributing Environmental Stressors and Emerging Antioxidant Therapeutic Interventions. Front Aging Neurosci 2022;14:827900. https://doi.org/10.3389/fnagi.2022.827900.

[8] Detcheverry F, Senthil S, Narayanan S, Badhwar A. Changes in levels of the antioxidant glutathione in brain and blood across the age span of healthy adults: A systematic review. Neuroimage Clin 2023;40:103503. https://doi.org/10.1016/j.nicl.2023.103503.

[9] Lushchak VI. Interplay between bioenergetics and oxidative stress at normal brain aging. Aging as a result of increasing disbalance in the system oxidative stress-energy provision. Pflugers Arch 2021;473:713–22. https://doi.org/10.1007/s00424-021-02531-4.

[10] Doshi SB, Agarwal A. The role of oxidative stress in menopause. J Midlife Health 2013;4:140–6. https://doi.org/10.4103/0976-7800.118990.

[11] Mink JW, Blumenschine RJ, Adams DB. Ratio of central nervous system to body metabolism in vertebrates: its constancy and functional basis. Am J Physiol 1981;241:R203–12. https://doi.org/10.1152/ajpregu.1981.241.3.R203.

[12] Cleeland C, Pipingas A, Scholey A, White D. Neurochemical changes in the aging brain: A systematic review. Neurosci Biobehav Rev 2019;98:306–19. https://doi.org/10.1016/j.neubiorev.2019.01.003.

[13] Grimm A, Eckert A. Brain aging and neurodegeneration: from a mitochondrial point of view. J Neurochem 2017;143:418–31. https://doi.org/10.1111/jnc.14037.

[14] Cichocka M, Bereś A. From fetus to older age: A review of brain metabolic changes across the lifespan. Ageing Res Rev 2018;46:60–73. https://doi.org/10.1016/j.arr.2018.05.005.

[15] Leech R, Sharp DJ. The role of the posterior cingulate cortex in cognition and disease. Brain 2014;137:12–32. https://doi.org/10.1093/brain/awt162.

[16] Rahim F, Khalafi M, Davoodi M, Shirbandi K. Metabolite changes in the posterior cingulate cortex could be a signature for early detection of Alzheimer's disease: a systematic review and meta-analysis study based on 1H-NMR. Egypt J Neurol Psychiatr Neurosurg 2023;59. https://doi.org/10.1186/s41983-023-00649-z.

[17] Bottino F, Lucignani M, Napolitano A, Dellepiane F, Visconti E, Rossi Espagnet MC, et al. In Vivo Brain GSH: MRS Methods and Clinical Applications. Antioxidants (Basel) 2021;10. https://doi.org/10.3390/antiox10091407.

[18] Pocernich CB, Butterfield DA. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta 2012;1822:625–30. https://doi.org/10.1016/j.bbadis.2011.10.003.

[19] Dwivedi D, Megha K, Mishra R, Mandal PK. Glutathione in Brain: Overview of Its Conformations, Functions, Biochemical Characteristics, Quantitation and Potential Therapeutic Role in Brain Disorders. Neurochem Res 2020;45:1461–80. https://doi.org/10.1007/s11064-020-03030-1.

[20] Harris AD, Saleh MG, Edden RAE. Edited 1 H magnetic resonance spectroscopy in vivo: Methods and metabolites. Magn Reson Med 2017;77:1377–89. https://doi.org/10.1002/mrm.26619.

[21] Cheng H, Wang A, Newman S, Dydak U. An investigation of glutamate quantification with PRESS and MEGA-PRESS. NMR Biomed 2021;34:e4453. https://doi.org/10.1002/nbm.4453.

[22] Rae CD. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem Res 2014;39:1–36. https://doi.org/10.1007/s11064-013-1199-5.

[23] Harris JL, Choi I-Y, Brooks WM. Probing astrocyte metabolism in vivo: proton

magnetic resonance spectroscopy in the injured and aging brain. Front Aging Neurosci 2015;7:202. https://doi.org/10.3389/fnagi.2015.00202.

[24] Duarte JMN, Lei H, Mlynárik V, Gruetter R. The neurochemical profile quantified by in vivo 1H NMR spectroscopy. Neuroimage 2012;61:342–62. https://doi.org/10.1016/j.neuroimage.2011.12.038.

[25] Haga KK, Khor YP, Farrall A, Wardlaw JM. A systematic review of brain metabolite changes, measured with 1H magnetic resonance spectroscopy, in healthy aging. Neurobiol Aging 2009;30:353–63. https://doi.org/10.1016/j.neurobiolaging.2007.07.005.

[26] Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357–67. https://doi.org/10.1016/S1474-4422(13)70044-9.

[27] Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207–16. https://doi.org/10.1016/S1474-4422(12)70291-0.

[28] McIntyre DJO, Charlton RA, Markus HS, Howe FA. Long and short echo time proton magnetic resonance spectroscopic imaging of the healthy aging brain. J Magn Reson Imaging 2007;26:1596–606. https://doi.org/10.1002/jmri.21198.

[29] Mekle R, Mlynárik V, Gambarota G, Hergt M, Krueger G, Gruetter R. MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med 2009;61:1279–85. https://doi.org/10.1002/mrm.21961.

[30] Pradhan S, Bonekamp S, Gillen JS, Rowland LM, Wijtenburg SA, Edden RAE, et al. Comparison of single voxel brain MRS AT 3T and 7T using 32-channel head coils. Magn Reson Imaging 2015;33:1013–8. https://doi.org/10.1016/j.mri.2015.06.003.

[31] Tkác I, Andersen P, Adriany G, Merkle H, Ugurbil K, Gruetter R. In vivo 1H NMR spectroscopy of the human brain at 7 T: 1H NMR Spectroscopy of the Human Brain. Magn Reson Med 2001;46:451–6. https://doi.org/10.1002/mrm.1213.

[32] Terpstra M, Cheong I, Lyu T, Deelchand DK, Emir UE, Bednařík P, et al. Test-retest reproducibility of neurochemical profiles with short-echo, single-voxel MR spectroscopy at 3T and 7T. Magn Reson Med 2016;76:1083–91. https://doi.org/10.1002/mrm.26022.

[33] Kaiser LG, Schuff N, Cashdollar N, Weiner MW. Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 T. Neurobiol Aging 2005;26:665–72. https://doi.org/10.1016/j.neurobiolaging.2004.07.001.

[34] Marjańska M, McCarten JR, Hodges J, Hemmy LS, Grant A, Deelchand DK, et al. Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using 1H magnetic resonance spectroscopy at 7 T. Neuroscience 2017;354:168–77. https://doi.org/10.1016/j.neuroscience.2017.04.035.

[35] Eylers VV, Maudsley AA, Bronzlik P, Dellani PR, Lanfermann H, Ding X-Q. Detection of normal aging effects on human brain metabolite concentrations and microstructure with whole-brain MR spectroscopic imaging and quantitative MR imaging. AJNR Am J Neuroradiol 2016;37:447–54. https://doi.org/10.3174/ajnr.A4557.

[36] Badhwar A, Tam A, Dansereau C, Orban P, Hoffstaedter F, Bellec P. Resting-state network dysfunction in Alzheimer's disease: A systematic review and meta-analysis. Alzheimers Dement 2017;8:73–85. https://doi.org/10.1016/j.dadm.2017.03.007.

[37] Tedeschi G, Righini A, Bizzi A, Barnett AS, Alger JR. Cerebral white matter in the centrum semiovale exhibits a larger N-acetyl signal than does gray matter in long echo time 1H-magnetic resonance spectroscopic imaging. Magn Reson Med 1995;33:127–33. https://doi.org/10.1002/mrm.1910330120.

[38] Kim HJ, Cho H, Park M, Kim JW, Ahn SJ, Lyoo CH, et al. MRI-visible perivascular spaces in the centrum semiovale are associated with brain amyloid deposition in patients with Alzheimer disease-related cognitive impairment. AJNR Am J Neuroradiol 2021;42:1231–8. https://doi.org/10.3174/ajnr.A7155.

[39] Sporn L, MacMillan EL, Ge R, Greenway K, Vila-Rodriguez F, Laule C. Longer repetition time proton MR spectroscopy shows increasing hippocampal and parahippocampal metabolite concentrations with aging. J Neuroimaging 2019;29:592–7. https://doi.org/10.1111/jon.12648.

[40] Rao SM, Losinski G, Mourany L, Schindler D, Mamone B, Reece C, et al. Processing speed test: Validation of a self-administered, iPad((R))-based tool for screening cognitive dysfunction in a clinic setting. Mult Scler 2017;23:1929–37.

[41] Marques JP, Kober T, Krueger G, van der Zwaag W, Van de Moortele P-F, Gruetter R. MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field. Neuroimage 2010;49:1271–81.

https://doi.org/10.1016/j.neuroimage.2009.10.002.

[42] Glick Y, Garg V. Centrum semiovale. Radiopaedia.org 2014. https://doi.org/10.53347/rid-30579.

[43] Gruetter R. Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magn Reson Med 1993;29:804–11. https://doi.org/10.1002/mrm.1910290613.

[44] Tkáč I, Deelchand D, Dreher W, Hetherington H, Kreis R, Kumaragamage C, et al. Water and lipid suppression techniques for advanced 1 H MRS and MRSI of the human brain: Experts' consensus recommendations. NMR Biomed 2021;34:e4459. https://doi.org/10.1002/nbm.4459.

[45] Tkáč I, Gruetter R. Methodology of H NMR spectroscopy of the human brain at very high magnetic fields. Appl Magn Reson 2005;29:139–57. https://doi.org/10.1007/BF03166960.

[46] Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods 2021;18:203–11. https://doi.org/10.1038/s41592-020-01008-z.

[47] Simpson R, Devenyi GA, Jezzard P, Hennessy TJ, Near J. Advanced processing and simulation of MRS data using the FID appliance (FID-A)-An open source, MATLAB-based toolkit. Magn Reson Med 2017;77:23–33. https://doi.org/10.1002/mrm.26091.

[48] Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001;14:260–4. https://doi.org/10.1002/nbm.698.

[49] Near J, Harris AD, Juchem C, Kreis R, Marjańska M, Öz G, et al. Preprocessing, analysis and quantification in single-voxel magnetic resonance spectroscopy: experts' consensus recommendations. NMR Biomed 2021;34:e4257. https://doi.org/10.1002/nbm.4257.

[50] Dhamala E, Abdelkefi I, Nguyen M, Hennessy TJ, Nadeau H, Near J. Validation of in vivo MRS measures of metabolite concentrations in the human brain. NMR Biomed 2019;32:e4058. https://doi.org/10.1002/nbm.4058.

[51] Rooney WD, Johnson G, Li X, Cohen ER, Kim S-G, Ugurbil K, et al. Magnetic field and tissue dependencies of human brain longitudinal 1H2O relaxation in vivo. Magn Reson Med 2007;57:308–18. https://doi.org/10.1002/mrm.21122.

[52] Bartha R, Michaeli S, Merkle H, Adriany G, Andersen P, Chen W, et al. In vivo 1H2O T2+ measurement in the human occipital lobe at 4T and 7T by Carr-Purcell MRI: detection of microscopic susceptibility contrast. Magn Reson Med 2002;47:742–50.

https://doi.org/10.1002/mrm.10112.

[53] Swanberg KM, Prinsen H, Coman D, de Graaf RA, Juchem C. Quantification of glutathione transverse relaxation time T2 using echo time extension with variable refocusing selectivity and symmetry in the human brain at 7 Tesla. J Magn Reson 2018;290:1–11. https://doi.org/10.1016/j.jmr.2018.02.017.

[54] Wilson M, Andronesi O, Barker PB, Bartha R, Bizzi A, Bolan PJ, et al. Methodological consensus on clinical proton MRS of the brain: Review and recommendations. Magn Reson Med 2019;82:527–50. https://doi.org/10.1002/mrm.27742.

[55] Wijtenburg SA, Rowland LM, Oeltzschner G, Barker PB, Workman CI, Smith GS. Reproducibility of brain MRS in older healthy adults at 7T. NMR Biomed 2019;32:e4040. https://doi.org/10.1002/nbm.4040.

[56] Wijtenburg SA, Near J, Korenic SA, Gaston FE, Chen H, Mikkelsen M, et al. Comparing the reproducibility of commonly used magnetic resonance spectroscopy techniques to quantify cerebral glutathione. J Magn Reson Imaging 2019;49:176–83. https://doi.org/10.1002/jmri.26046.

[57] Shukla D, Mandal PK, Ersland L, Grüner ER, Tripathi M, Raghunathan P, et al. A multi-center study on human brain glutathione conformation using magnetic resonance spectroscopy. J Alzheimers Dis 2018;66:517–32. https://doi.org/10.3233/JAD-180648.

[58] Dash UC, Bhol NK, Swain SK, Samal RR, Nayak PK, Raina V, et al. Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications. Acta Pharm Sin B 2025;15:15–34. https://doi.org/10.1016/j.apsb.2024.10.004.

[59] Teleanu DM, Niculescu A-G, Lungu II, Radu CI, Vladâcenco O, Roza E, et al. An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases. Int J Mol Sci 2022;23:5938. https://doi.org/10.3390/ijms23115938.

[60] Trofin D-M, Sardaru D-P, Trofin D, Onu I, Tutu A, Onu A, et al. Oxidative stress in brain function. Antioxidants (Basel) 2025;14. https://doi.org/10.3390/antiox14030297.

[61] Abadin X, de Dios C, Zubillaga M, Ivars E, Puigròs M, Marí M, et al. Neuroinflammation in age-related neurodegenerative diseases: Role of mitochondrial oxidative stress. Antioxidants (Basel) 2024;13:1440. https://doi.org/10.3390/antiox13121440.

[62] Lally N, An L, Banerjee D, Niciu MJ, Luckenbaugh DA, Richards EM, et al. Reliability of 7T[1]H-MRS measured human prefrontal cortex glutamate, glutamine, and glutathione signals using an adapted echo time optimized PRESS sequence: A between- and

within-sessions investigation. Journal of Magnetic Resonance Imaging 2016;43:88–98. https://doi.org/10.1002/jmri.24970.

[63] Zhu X-H, Qiao H, Du F, Xiong Q, Liu X, Zhang X, et al. Quantitative imaging of energy expenditure in human brain. Neuroimage 2012;60:2107–17. https://doi.org/10.1016/j.neuroimage.2012.02.013.

[64] Mosharov EV, Rosenberg AM, Monzel AS, Osto CA, Stiles L, Rosoklija GB, et al. A human brain map of mitochondrial respiratory capacity and diversity. Nature 2025;641:749–58. https://doi.org/10.1038/s41586-025-08740-6.

[65] Bennett CF, Latorre-Muro P, Puigserver P. Mechanisms of mitochondrial respiratory adaptation. Nat Rev Mol Cell Biol 2022;23:817–35. https://doi.org/10.1038/s41580-022-00506-6.

[66] Lind A, Boraxbekk C-J, Petersen ET, Paulson OB, Siebner HR, Marsman A. Regional myo-inositol, creatine, and choline levels are higher at older age and scale negatively with visuospatial working memory: A cross-sectional proton MR spectroscopy study at 7 Tesla on normal cognitive ageing. J Neurosci 2020;40:8149–59. https://doi.org/10.1523/JNEUROSCI.2883-19.2020.

[67] Raj D, Yin Z, Breur M, Doorduin J, Holtman IR, Olah M, et al. Increased white matter inflammation in aging- and Alzheimer's disease brain. Front Mol Neurosci 2017;10:206. https://doi.org/10.3389/fnmol.2017.00206.

[68] Wang Q, Schindler SE, Chen G, Mckay NS, McCullough A, Flores S, et al. Investigating white matter neuroinflammation in Alzheimer disease using diffusion-based neuroinflammation imaging. Neurology 2024;102:e208013. https://doi.org/10.1212/WNL.0000000000208013.

[69] De Stefano N, Narayanan S, Mortilla M, Guidi L, Bartolozzi ML, Federico A, et al. Imaging axonal damage in multiple sclerosis by means of MR spectroscopy. Neurol Sci 2000;21:S883–7. https://doi.org/10.1007/s100720070031.

[70] Gong T, Hui SCN, Zöllner HJ, Britton M, Song Y, Chen Y, et al. Neurometabolic timecourse of healthy aging 2022. https://doi.org/10.1101/2022.06.08.495050.

[71] McMorris T, Hale BJ, Pine BS, Williams TB. Creatine supplementation research fails to support the theoretical basis for an effect on cognition: Evidence from a systematic review. Behav Brain Res 2024;466:114982. https://doi.org/10.1016/j.bbr.2024.114982.

[72] Gualano B, Rawson ES, Candow DG, Chilibeck PD. Creatine supplementation in the aging population: effects on skeletal muscle, bone and brain. Amino Acids 2016;48:1793–805. https://doi.org/10.1007/s00726-016-2239-7.

[73] Mahmoudi N, Dadak M, Bronzlik P, Maudsley AA, Sheriff S, Lanfermann H, et al. Microstructural and metabolic changes in normal aging human brain studied with combined whole-brain MR spectroscopic imaging and quantitative MR imaging. Clin Neuroradiol 2023;33:993–1005. https://doi.org/10.1007/s00062-023-01300-3.

[74] Rawson ES, Clarkson PM, Price TB, Miles MP. Differential response of muscle phosphocreatine to creatine supplementation in young and old subjects: Creatine supplementation in older men. Acta Physiol Scand 2002;174:57–65. https://doi.org/10.1046/j.1365-201x.2002.00924.x.

[75] Gasiorowska A, Wydrych M, Drapich P, Zadrozny M, Steczkowska M, Niewiadomski W, et al. The biology and pathobiology of glutamatergic, cholinergic, and dopaminergic signaling in the aging brain. Front Aging Neurosci 2021;13:654931. https://doi.org/10.3389/fnagi.2021.654931.

[76] Garabadu D, Agrawal N, Sharma A, Sharma S. Mitochondrial metabolism: a common link between neuroinflammation and neurodegeneration. Behav Pharmacol 2019;30:642–52. https://doi.org/10.1097/FBP.0000000000000505.

[77] Charlton RA, Barrick TR, McIntyre DJ, Shen Y, O'Sullivan M, Howe FA, et al. White matter damage on diffusion tensor imaging correlates with age-related cognitive decline. Neurology 2006;66:217–22. https://doi.org/10.1212/01.wnl.0000194256.15247.83.

[78] Marsman A, Mandl RCW, van den Heuvel MP, Boer VO, Wijnen JP, Klomp DWJ, et al. Glutamate changes in healthy young adulthood. Eur Neuropsychopharmacol 2013;23:1484–90. https://doi.org/10.1016/j.euroneuro.2012.11.003.

[79] Matias I, Diniz LP, Araujo APB, Damico IV, de Moura P, Cabral-Miranda F, et al. Age-associated upregulation of glutamate transporters and glutamine synthetase in senescent astrocytes in vitro and in the mouse and human hippocampus. ASN Neuro 2023;15:17590914231157974. https://doi.org/10.1177/17590914231157974.

[80] Maragakis NJ, Rothstein JD. Glutamate transporters in neurologic disease. Arch Neurol 2001;58:365–70. https://doi.org/10.1001/archneur.58.3.365.

[81] Hädel S, Wirth C, Rapp M, Gallinat J, Schubert F. Effects of age and sex on the concentrations of glutamate and glutamine in the human brain. J Magn Reson Imaging 2013;38:1480–7. https://doi.org/10.1002/jmri.24123.

[82] Mosconi L, Berti V, Dyke J, Schelbaum E, Jett S, Loughlin L, et al. Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. Sci Rep 2021;11:10867. https://doi.org/10.1038/s41598-021-90084-y.

[83] Borrás C, Gambini J, López-Grueso R, Pallardó FV, Viña J. Direct antioxidant and

protective effect of estradiol on isolated mitochondria. Biochim Biophys Acta 2010;1802:205–11. https://doi.org/10.1016/j.bbadis.2009.09.007.

[84] Karim R, Stanczyk FZ, Hodis HN, Cushman M, Lobo RA, Hwang J, et al. Associations between markers of inflammation and physiological and pharmacological levels of circulating sex hormones in postmenopausal women. Menopause 2010;17:785–90. https://doi.org/10.1097/gme.0b013e3181cc50b2.

[85] Goyette MJ, Murray SL, Saldanha CJ, Holton K. Sex hormones, neurosteroids, and glutamatergic neurotransmission: A review of the literature. Neuroendocrinology 2023;113:905–14. https://doi.org/10.1159/000531148.

[86] Bendis PC, Zimmerman S, Onisiforou A, Zanos P, Georgiou P. The impact of estradiol on serotonin, glutamate, and dopamine systems. Front Neurosci 2024;18:1348551. https://doi.org/10.3389/fnins.2024.1348551.

[87] Davis SR, Baber RJ. Treating menopause - MHT and beyond. Nat Rev Endocrinol 2022;18:490–502. https://doi.org/10.1038/s41574-022-00685-4.

[88] Martínez de Toda I, González-Sánchez M, Díaz-Del Cerro E, Valera G, Carracedo J, Guerra-Pérez N. Sex differences in markers of oxidation and inflammation. Implications for ageing. Mech Ageing Dev 2023;211:111797. https://doi.org/10.1016/j.mad.2023.111797.

[89] Noss MM, Millwood SN, Kuhlman KR. Women with lower systemic inflammation demonstrate steeper cognitive decline with age: Results from a large prospective, longitudinal sample. Brain Behav Immun Health 2022;22:100465. https://doi.org/10.1016/j.bbih.2022.100465.

[90] Logue E, Nemeroff CB. Sex differences in the associations among early life adversity, inflammation, and cognition. Biomolecules 2025;15. https://doi.org/10.3390/biom15020161.

[91] Marjańska M, Emir UE, Deelchand DK, Terpstra M. Faster metabolite (1)H transverse relaxation in the elder human brain. PLoS One 2013;8:e77572. https://doi.org/10.1371/journal.pone.0077572.

[92] Soules M, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric 2001;4:267–72. https://doi.org/10.1080/cmt.4.4.267.272.

ACKNOWLEDGMENTS

The authors would like to thank Ali Filali-Mouhim, PhD, from the Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal (CRIUGM) for his input in the statistical analysis, and Lianne Trigiani, PhD, for reading and providing feedback on the manuscript.

CONFLICT OF INTEREST STATEMENT

All authors declare that they have no financial, personal, or competing interests/conflicts.

CONSENT STATEMENT

Ethical approval was obtained from the aging-neuroimaging research ethics committee of the CIUSSS du Centre-Sud-de-île-de-Montréal (CIUSSS-CSMTL)*,* and from the McGill University Institutional Review Board, Faculty of Medicine and Health Sciences. Written informed consent was obtained from all participants.

FUNDING SOURCES

This work was supported by the Réseau de Bio-Imagerie du Québec (RBIQ) Pilot Grant, the Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal (CRIUGM) programme d'appui à des Projets de Recherche Stratégiques et Structurants (PRSS), and the Fonds de Recherche Québec – Santé (FRQS) (A.B); the Canadian Institutes of Health Research grant (CIHR) (S.N., #153005); as well as FRQS Chercheurs boursiers Junior 1 and 2, and the Fonds de soutien à la recherche pour les neurosciences du vieillissement from the Fondation Courtois (A.B.); and the FRQS bourse de formation au doctorat (2024) (#352199, F.E.D.; #332672, S.S).

KEYWORDS